[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Isala\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":217},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,70,99,121,143,167,194],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100632225","cgm-in-acute-ischemic-stroke-100632225",false,"NCT07510919","CGM in Acute Ischemic Stroke","Continuous Glucose Monitoring for Enhanced Management of Hyperglycemia in Persons With Type 2 Diabetes Undergoing Endovascular Therapy for Acute Ischemic Stroke: a Randomized Controlled Trial.","SENSTROKE","Inclusion Criteria:\n\n* Age ≥18 years\n* Acute ischemic stroke treated with endovascular therapy (EVT)\n* Type 2 diabetes mellitus, defined as one of the following:\n* documented diagnosis of type 2 diabetes mellitus\n* use of glucose-lowering medication\n* admission plasma glucose ≥11.1 mmol\u002FL\n* HbA1c ≥48 mmol\u002Fmol (≥6.5%)\n\nExclusion Criteria:\n\n* Current pregnancy\n* Extensive skin infections or dermatological conditions at the intended sensor site\n* Medical situations known to interfere with CGM accuracy, including:\n* Hypotension defined as a systolic blood pressure \\\u003C100 mmHg at 30 and 60 minutes after admission\n* Dialysis treatment\n* Estimated glomerular filtration rate (eGFR) \\\u003C15 mL\u002Fmin\u002F1.73 m²\n* Use of medications known to interfere with CGM accuracy, including:\n* Acetaminophen \\>4 g\u002Fday\n* Dopamine\n* High-dose vitamin C (ascorbic acid)\n* Hydroxyurea \u002F hydroxycarbamide\n* Clinically relevant pancreatic disease\n* Systemic glucocorticoid therapy with a prednisone-equivalent dose \\>5 mg\u002Fday\n* Expected admission to an intensive care unit (ICU)","ALL","18 Years",{"count":20,"type":21},82,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this randomized clinical trial is to evaluate whether continuous glucose monitoring (CGM) can be used to guide glucose management in patients with type 2 diabetes who are admitted with an acute ischemic stroke and undergo endovascular therapy. Hyperglycemia frequently occurs during hospitalization in stroke and is associated with worse neurological and clinical outcomes. In current clinical practice, glucose levels are monitored using intermittent point-of-care testing (POCT) with finger-prick measurements, which may miss clinically relevant glucose fluctuations. CGM provides continuous glucose measurements and may allow earlier detection of hyperglycemia and more timely glucose management.\n\nThis study is designed as a non-inferiority randomized controlled trial comparing CGM-guided glucose management with standard POCT-guided glucose management. The primary objective is to determine whether CGM-guided glucose management is non-inferior to POCT-guided management in terms of percentage time spent in hyperglycemia (glucose \\>10 mmol\u002FL) during the first 72 hours of hospitalization.\n\nResearchers will compare CGM-guided glucose management to POCT-guided glucose management to evaluate whether CGM can be used as an alternative strategy to guide glucose control in hospitalized stroke patients.\n\nParticipants will:\n\n* Be randomly assigned to either CGM-guided glucose management or standard POCT-guided glucose management\n* Have their glucose levels continuously monitored (blinded in the POCT-guided group) during hospitalization\n* Receive glucose management according to the assigned monitoring strategy, based on the hospital insulin protocol",[27,28,29,30,31],"Acute Ischemic Stroke","Diabetes (DM)","Diabetes Type 2","Hyperglycemia","Stroke","NOT_YET_RECRUITING","2026-03-31",{"date":35,"type":36},"2026-04-06","ACTUAL",{"date":38,"type":21},"2026-04",{"date":40,"type":21},"2028-08",{"name":42,"class":43},"Isala","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100518491","phase-4-evaluating-the-safety-of-shortened-infusion-times-for-different-oncological-immunotherapie-100518491","NCT06031233","Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie","Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapies; An Observational Prospective Study","MINUTE","Inclusion Criteria:\n\n* Starting treatment with monoclonal antibodies: nivolumab, pembrolizumab ipilimumab, bevacizumab, trastuzumab, durvalumab or atezolizumab.\n* 18 years and older.\n* No known history of increased susceptibility to immunological reactions.\n* Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.\n\nExclusion Criteria:\n\n* Other research medication within 4 weeks of the start of the study.\n* Inclusion in medical research in which the administration of medication should follow its stated times and dosages of infusions\n* Dosage deviates from standard protocol\n* Patients whom receive drugs through a central venous catheter (and for example porth-a-cath).",{"count":53,"type":21},776,[55],"PHASE4","This study is an interventional, explorative, prospective study to show whether shortening of infusion times for patients using nivolumab, pembrolizumab, ipilimumab, trastuzumab, bevacizumab, durvalumab or atezolizumab continues to be associated with an acceptable safety profile.\n\nInfusion times will be gradually shortened if tolerability allowes.",[58,59],"Oncology","Infusion Reaction","RECRUITING","2026-03-25",{"date":63,"type":36},"2026-03-30",{"date":65,"type":36},"2023-09-01",{"date":67,"type":21},"2028-12",{"name":42,"class":43},1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":98,"locationsCount":69},"100612430","correlation-of-diaphragm-shear-wave-elastography-with-transdiaphragmatic-pressure-in-healthy-adults-a-feasibility-study-100612430","NCT07253480","Correlation of Diaphragm Shear-Wave Elastography With Transdiaphragmatic Pressure in Healthy Adults: a Feasibility Study","PLEASSURE 1","Inclusion Criteria:\n\n* 18-60 years, BMI 18-30 kg\u002Fm²\n* No known respiratory, neuromuscular, or cardiothoracic disease\n* Able to perform inspiratory maneuvers and consent.\n\nExclusion Criteria:\n\n* Pregnancy\n* History of smoking (\\> 10 pack years)\n* Impaired swallowing, as well as esophageal diseases, or disorders at the level of the gastroesophageal sphincter",true,"60 Years",{"count":80,"type":21},12,"OBSERVATIONAL","Changes in intrapleural pressure after lung volume reduction in Chronic Obstructive Pulmonary disease (COPD) patients can lead to complications, including an increased risk of pneumothorax. This procedure, intended to improve lung function, may disturb the pressure balance within the pleural space, potentially precipitating pneumothorax. Careful monitoring of intrapleural pressure could help predict patients at risk. However, intrapleural pressure can currently only be measured invasively. Diaphragm shear-wave elastography (SWE) has been shown to reflect transdiaphragmatic pressure during isovolumetric inspiratory efforts and ventilation against inspiratory loading, and therefore may serve as a non-invasive surrogate for intrapleural pressure. This project outlines a stepwise study plan to evaluate SWE as a tool for intrapleural pressure monitoring (Figure 1). The project only moves to the next phase is the study previous phase was achieved successfully. The current protocol involves the first phase: to validate diaphragm SWE against transdiaphragmatic pressure and assess measurement reliability for local ultrasound systems in healthy adults.This prospective, single-centre, observational validation study will include twelve healthy adult volunteers. During a single study session, participants will perform standardized inspiratory efforts while simultaneous measurements of diaphragm SWE, transdiaphragmatic pressure (via esophageal and gastric balloon catheters), and mouth pressures are obtained. These methods are routinely applied in physiological research and carry minimal risk. Apart from brief nasal or throat discomfort during catheter placement, no significant adverse effects are expected. By establishing the relationship between diaphragm SWE, transdiaphragmatic pressure, and mouth pressures, this study aims to provide the essential validation step for future clinical research in COPD patients following lung volume reduction.",[84,85,86],"Diaphragm Ultrasound","Diaphragm Dysfunction","Health Adult Subjects",[88,89,90,91],"diaphragm","ultrasound","diaphragmatic pressure","shear-wave elastography","2025-11-29",{"date":94,"type":36},"2025-12-05",{"date":38,"type":21},{"date":97,"type":21},"2026-09",{"name":42,"class":43},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},"100612868","ultrasound-of-the-diaphragm-excursion-ratio-as-physiological-biomarker-in-acute-exacerbations-of-chronic-obstructive-pulmonary-disease-100612868","NCT07259174","Ultrasound of the Diaphragm Excursion Ratio as Physiological Biomarker in Acute Exacerbations of Chronic Obstructive Pulmonary Disease","Undated 2","• Inclusion criteria:\n\nIn order to be eligible to participate in this study, a subject must meet all of the following criteria:\n\n* Hospitalization primarily because of severe acute exacerbation of COPD\n* Spirometry record within last 5 years, with: post-bronchodilator FEV1\u002FFVC \\\u003C 0,70 and FEV1% \\\u003C 80%predicted\n* Minimum of 10 packyears\n\n  * Exclusion criteria:\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study:\n\n* Established diagnosis of diaphragm diaphragm paralysis.\n* Inability for diaphragm imaging (e.g. mechanical ventilation, or unable to follow vocal instructions).\n* Those not able or unwilling to give written informed consent.\n* Pregnant women",{"count":107,"type":21},186,"3.1 Introduction and rationale In 2020 an estimate of 562.700 people had Chronic Obstructive Pulmonary Disease (COPD) in the Netherlands, resulting in 21.335 hospital admissions.\\[1\\] An acute exacerbation COPD (AECOPD) in combination with hospital admission is associated with high mortality and morbidity. \\[2\\]\n\nNoninvasive ventilation (NIV) has been very effective in the context of AECOPD, since it efficiently offloads respiratory muscles and counteracts dynamic hyperinflation. This method often prevents intubation as a bridge to administering effective therapies (e.g., glucocorticoids, bronchodilators, and antibiotic agents)\\[3\\], and may reduce mortality.\\[4\\] Current guidelines recommend NIV for the treatment of acute respiratory failure in patients with respiratory distress, pH \\\u003C 7.35, and PaCO2 \\> 6 kPA (with exclusion of patients requiring invasive ventilation, see guideline).\\[5,6\\] National guidelines do not recommend NIV in AECOPD with increased work of breathing without respiratory acidosis due to lack of evidence. \\[5\\]\n\nUltrasound of the diaphragm can identify atrophy and impaired motion or contractility of the diaphragm\\[10\\], and has been shown to predict mortality and NIV failure during NIV treatment for respiratory acidosis due to AECOPD.\\[11-15\\] Whether ultrasound of the diaphragm may predict mortality or need for (non-)invasive ventilation in AECOPD without respiratory acidosis on initial presentation is unknown.\n\nDuring exploratory analysis of a previous study (unpublished; NCT05671198) we might have found a marker that has the potential to predict progression to NIV or death during hospitalization for AECOPD without respiratory acidosis:\n\nThe difference between diaphragm motion during tidal breathing and maximal breathing, used as a surrogate for inspiratory reserve volume (IRV), was significantly lower in patients requiring NIV or who died in-hospital compared to those who did not (1.59 cm, SD 1.91 vs. 3.14 cm, SD 2.45; p = 0.033). We performed a ROC curve analysis to assess the predictive value of these variables, which yielded an area under the ROC curve (AUROC) of 0.752 (95% CI: 0.535 - 0.968, p = 0.033), indicating a statistically significant discriminatory ability. The best cut-off value, as determined with the Youden's J statistic, was 1.74 cm, with a sensitivity of 86% and specificity of 70% for predicting NIV requirement or inhospital death.\n\nHowever, the number of events was low and the study was primarily powered for another outcome. Therefore, prospective validation is needed before we impose treatment based on this marker. In case the suggested ultrasound measurement (see introduction) proofs to be a discriminatory marker for deterioration during hospitalization or predictive of progression to Non-Invasive Ventilation, we hope to be able to perform a follow-up study in which patient will be randomized to either standard of care or 'elective' NIV (to avoid emergency NIV need) based on yet to determine cut-off values.\n\n3.2 Design (including population, method, confounders and outcomes) A multi-center, prospective observational cohort study conducted at Isala Hospital and UMCG aimed at determining the value of the sonographic motion ratio (tidal\u002Fmaximum) of the diaphragm in AECOPD after hospital admission. After enrollment, the sonographic diaphragm motion will be assessed as additional measurement during standard-of-care lung ultrasound (POCUS), after which hospital outcomes will be registered. Primary outcome will be the sensitivity of this ultrasound marker for in-hospital deterioration (progression to NIV of death). Secondary analysis will include predictive models.\n\n3.3 Research question What is the sensitivity of the diaphragm motion ratio (tidal\u002Fmaximum) during ultrasound for in-hospital deterioration (progression to NIV or death) in AECOPD.",[110],"COPD",[88,89,110],"2025-11-26",{"date":114,"type":36},"2025-12-02",{"date":116,"type":36},"2025-10-14",{"date":118,"type":21},"2026-12",{"name":42,"class":43},2,{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100602513","early-mindfulness-based-cognitive-therapy-for-prevention-of-psychological-distress-in-cancer-patients-100602513","NCT07124481","Early Mindfulness Based Cognitive Therapy for Prevention of Psychological Distress in Cancer Patients","EarlyMind","Inclusion Criteria:\n\n* Diagnosed with urological cancer or breast cancer\n* \\\u003C6 weeks since cancer diagnosis\n* Planned curative treatment or palliative treatment with life expectation \\>1 year\n* Good proficiency in Dutch language\n\nExclusion Criteria:\n\n* Serious psychiatric history or current psychiatric treatment (interfering with study participation): 1) current suicidal ideation, 2) current psychosis or bipolar disorder, 3) psychosis or bipolar disorder in history\n* Unable to understand study procedure\n* A priori unable to be available for 8 week MBCT",{"count":129,"type":21},208,[24],"The goal of this clinical trial is to learn if early provision of mindfulness based cognitive therapy can prevent psychological distress in adult patients with cancer one year after diagnosis.\n\nResearchers will compare mindfulness based cognitive therapy to usual care to see if psychological distress is lower in patients that followed mindfulness.\n\nParticipants will follow 8 weekly sessions of mindfulness and fill in questionnaires.",[133,134],"Cancer","Mindfulness Based Cognitive Therapy","2025-08-08",{"date":137,"type":36},"2025-08-15",{"date":139,"type":21},"2025-10",{"date":141,"type":21},"2027-10",{"name":42,"class":43},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":166},"100542436","direct-superior-approach-versus-posterolateral-approach-in-total-hip-arthroplasty-splash-100542436","NCT06342843","Direct Superior Approach Versus PosteroLateral Approach in Total Hip Arthroplasty (SPLAsH)","Direct Superior Approach Versus PosteroLateral Approach in Total Hip Arthroplasty: a Multicenter Double Blinded Randomized Controlled Trial","SPLAsH","Inclusion Criteria:\n\nSubject\n\n* Has symptomatic incapacitating coxarthrosis in whom total hip arthroplasty (THA) is indicated, diagnosed by both physical examination and pelvic\u002Fhip X-ray\n* Has signed informed consent\n* Is ageing 18 years or older at time of study entry\n* Is competent and able to participate in follow-up\n\nExclusion Criteria:\n\n* Previous ipsilateral hip surgery\n* BMI \\>35 kg\u002Fm2\n* Contralateral incapacitating coxarthrosis, diagnosed by both physical examination and pelvic\u002Fhip X-ray\n* Neurological conditions influencing walking pattern\n* Inability to walk without walking aid preoperatively\n* Rheumatoid arthritis (RA)\n* Severe hip dysplasia\n* Cognitive impairment\n* Malignancies or metastases involving the hip joint or the nearby soft tissues\n* Inability to speak and write Dutch language","99 Years",{"count":153,"type":21},211,[24],"This study will compare postoperative pain, health related quality of life (HRQoL), function, rehabilitation, urinary incontinence, muscle atrophy and component positioning in total hip arthroplasty (THA) using the posterolateral approach (PLA) or the direct superior approach (DSA). In addition, the CT images will be used to validate a new metal artefact reduction technique.",[157],"Osteoarthritis, Hip","2025-07-30",{"date":160,"type":36},"2025-08-03",{"date":162,"type":36},"2024-03-26",{"date":164,"type":21},"2027-12-31",{"name":42,"class":43},3,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":176,"briefSummary":177,"conditions":178,"keywords":181,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":120},"100422449","use-of-physiology-to-evaluate-procedural-result-after-pci-cto-100422449","NCT04780971","Use of Physiology to Evaluate Procedural Result After PCI CTO","ULTRA-CTO","Inclusion Criteria:\n\n1. Age 18 years and older.\n2. Angiographically successful PCI CTO without any remaining lesion at least 30% proximal to the stented segment.\n3. Possibility to perform physiologic measurements and OCT of sufficient quality.\n4. Patients willing and capable to provide written informed consent.\n\nExclusion Criteria:\n\n1\\) Contra-indication for adenosine.",{"count":175,"type":21},200,[24],"ULTRA-CTO is a prospective multicentre non-randomised investigator-initiated trial designed to enrol 200 subjects with an indication for percutaneous coronary intervention (PCI) of chronic total occluded (CTO) coronary artery.\n\nThe main objective of the study is to assess the predictive value of post-PCI resting full-cycle ratio (RFR) and fractional flow reserve (FFR) with regard to Fractional flow reserve (SSR) in CTO patients.",[179,180],"Percutaneous Coronary Revascularisation","Complex Coronary Lesion",[182,183,184,185],"percutaneous coronary intervention","chronic total occlusion","intra-coronary physiology","optical coherence tomography","2025-02-15",{"date":188,"type":36},"2025-02-19",{"date":190,"type":36},"2021-07-21",{"date":192,"type":21},"2026-06",{"name":42,"class":43},{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":69},"100490828","sonographic-diaphragm-function-in-aecopd-100490828","NCT05671198","Sonographic Diaphragm Function in AECOPD","Ultrasound of the Diaphragm As Physiological Biomarker in Acute Exacerbations of Chronic Obstructive Pulmonary Disease","UNDATED","Inclusion Criteria:\n\n* Hospitalisation primarily because of severe acute exacerbation of COPD\n* COPD, according to GOLD 2018 definition\n* Post-bronchodilator FEV1\u002FFVC \\\u003C 0,70 and FEV1% \\\u003C 80%pred. within last 5 years\n\nExclusion Criteria:\n\n* Respiratory acidosis (pH \\\u003C 7.35 ánd PaCO2 \\> 6 kPA)\n* Need for (non-)invasive ventilation based on other criteria (e.g. severe hypoxia) upon presentation.\n* Established diagnosis of diaphragm diaphragm paralysis.\n* Inability for diaphragm imaging (e.g. mechanical ventilation, or unable to follow vocal instructions).\n* Those not able or unwilling to give written informed consent.\n* Pregnant women",{"count":203,"type":21},51,"The study will be conducted as a single-center, prospective cohort study. The primary objective of this study is to investigate the responsiveness of sonographic parameters of diaphragm to detect change in Borg score for dyspnea during hospitalisation for AECOPD without respiratory acidosis.",[206],"Copd",[88,110,208],"thoracic ultrasound","2024-10-02",{"date":211,"type":36},"2024-10-04",{"date":213,"type":36},"2023-03-27",{"date":215,"type":21},"2025-08",{"name":42,"class":43},""]